Drug Search Results
More Filters [+]

Glecaprevir

Alternative Names: glecaprevir, abt-493, mavyret
Latest Update: 2024-09-26
Latest Update Note: News Article

Product Description

Glecaprevir is a direct acting antiviral agent and Hepatitis C virus (HCV) NS3/4A protease inhibitor that targets the the viral RNA replication. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Glecaprevir)

Mechanisms of Action: HCV-NS3/4A Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Canada | Croatia | Cyprus | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Israel | Italy | Japan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay

Approved Indications: Liver Cirrhosis | Hepatitis | Hepatitis, Chronic | Hepatitis C | Hepatitis C, Chronic

Known Adverse Events: Headache

Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additonal Commercial Interests: Enanta

Clinical Description

Map of Global Clinical Trials for Glecaprevir

Countries in Clinic: Australia, Austria, Brazil, Canada, China, France, Germany, Italy, Korea, New Zealand, Russia, Spain, Sweden, Switzerland, United Kingdom, United States

Active Clinical Trial Count: 7

Highest Development Phases

Phase 3: Hepatitis A|Hepatitis C|Hepatitis C, Chronic

Phase 2: Communicable Diseases|HIV Infections|Kidney Failure, Chronic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

M20-350

P3

Active, not recruiting

Hepatitis C|Hepatitis A

2024-08-26

32%

M20-350

P3

Active, not recruiting

Hepatitis C|Hepatitis A

2024-08-26

32%

2020-005777-27

P3

Active, not recruiting

Hepatitis C

2024-04-22

PURGE-C

P2

Completed

Hepatitis C|Hepatitis A|Communicable Diseases|HIV Infections

2023-05-18

THINKER

P2

Completed

Kidney Failure, Chronic|Hepatitis C, Chronic

2022-03-01

Recent News Events